New Delhi: Biological E can apply for a license for emergency use by the end of August. By December 2021, it will supply 30 crore doses to the Government of India. According to sources, Hyderabad-based pharmaceutical company Biological E’s vaccine Corbevax is likely to be launched in India by the end of September. According to ANI sources, the company has started the Phase 3 trial. The Government of India has already made advance booking for the clinical study of Phase 3 of the Covid-19 vaccine Corbevacs of Biologicals E.
Union Minister of State (Health) Dr. Bharti Praveen Pawar says that the Government of India will also provide financial assistance to the domestic vaccine Biological E. By 2021, India will receive 300 million doses of the vaccine running on Phase 3’s advanced clinical trial. The news comes after experts have urged the government to expedite immunization and maintain practices related to COVID-19 (wearing of masks, maintaining physical distance, and creating containment zones) to curb the expected third wave. Could. There is a fear of knocking in the country in September.
We, Will, have to prepare for the third wave
The committee of experts has requested that health infrastructure is of utmost importance. So that 4 lakh cases can be handled daily. With this, about 2 lakh ICU beds and 1 lakh ventilator beds will be required. Along with this, protocols related to vaccination and Kovid will also have to be continued.
23 thousand crore Kovid Management Package has been announced to control the situation of Covid-19 and improve the health infrastructure of the country. States have also been directed to send plans for health infrastructure, on the basis of which financial assistance will be provided to the states immediately. At the same time, 43.51 crore doses of the Covid-19 vaccine have been administered in India so far.
